Unicycive Therapeutics Inc (NASDAQ: UNCY) kicked off on Monday, up 20.24% from the previous trading day, before settling in for the closing price of $0.41. Over the past 52 weeks, UNCY has traded in a range of $0.20-$1.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -5.80% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 42.97%. With a float of $84.53 million, this company’s outstanding shares have now reached $94.36 million.
In an organization with 14 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 264.21%, operating margin of 10647.97%, and the pretax margin is 8601.85%.
Unicycive Therapeutics Inc (UNCY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Unicycive Therapeutics Inc is 10.41%, while institutional ownership is 35.89%.
Unicycive Therapeutics Inc (UNCY) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.13 earnings per share (EPS), lower than consensus estimate (set at -0.12) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.97% per share during the next fiscal year.
Unicycive Therapeutics Inc (NASDAQ: UNCY) Trading Performance Indicators
Take a look at Unicycive Therapeutics Inc’s (UNCY) current performance indicators. Last quarter, stock had a quick ratio of 3.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Unicycive Therapeutics Inc (UNCY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.69 million. That was better than the volume of 1.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.83%. Additionally, its Average True Range was 0.04.
During the past 100 days, Unicycive Therapeutics Inc’s (UNCY) raw stochastic average was set at 49.67%, which indicates a significant decrease from 96.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 94.04% in the past 14 days, which was lower than the 132.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3899, while its 200-day Moving Average is $0.8118. However, in the short run, Unicycive Therapeutics Inc’s stock first resistance to watch stands at $0.5310. Second resistance stands at $0.5631. The third major resistance level sits at $0.6211. If the price goes on to break the first support level at $0.4409, it is likely to go to the next support level at $0.3829. The third support level lies at $0.3508 if the price breaches the second support level.
Unicycive Therapeutics Inc (NASDAQ: UNCY) Key Stats
The company with the Market Capitalisation of 47.09 million has total of 37,607K Shares Outstanding. Its annual sales at the moment are 680 K in contrast with the sum of -30,540 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was 9,860 K.
